论文部分内容阅读
目的:比较利加隆与易善力在TACE中的预防和治疗肝功能损害的疗效。方法:肝癌患者100例,随机分为两组。利加隆组50例(男性41例,女性9例,年龄40a±s14a)TACE术前5～7d开始服用利加隆140mg,tid,疗程15～20d。易善力组50例(男性39例,女性11例,年龄37a±s14a)TACE术前5～7d开始服用易善力600mg,tid,疗程同上。结果:TACE术后3天利加隆组黄疸、ALT、TBA、r-GT等变化均小于易善力组(P<0.05或0.01),术后10天利加隆组肝区疼痛、黄疸、ALT、ALB、TBA等变化均优于易善力组(P<0.05或0.01)。结论:利加隆在TACE中预防和治疗肝功能损害的疗效优于易善力。
OBJECTIVE: To compare the efficacy of Ligarene and Isonelan in the prevention and treatment of liver dysfunction in TACE. Methods: 100 patients with liver cancer were randomly divided into two groups. Fifty patients (41 males and 9 females, age 40a ± s14a) were given lialone for 5 ~ 7 days before TACE. Yishenli group 50 cases (39 males, 11 females, age 37a ± s14a) 5 ~ 7d before TACE 5 ~ 7 days to take Yi Shan Li 600mg, tid, the same treatment. Results: The changes of jaundice, ALT, TBA and r-GT in the LEGA group were all less than those in the EZ group (P <0.05 or 0.01) 3 days after TACE. The pain, jaundice, ALT, ALB, TBA and other changes were better than the Yishenli group (P <0.05 or 0.01). Conclusions: Ligarene is superior to encephalitis in preventing and treating liver damage in TACE.